Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

about

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

Item

http://www.wikidata.org/entity/Q47771973

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

@en

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

@nl

type

Item

label

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

@en

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

@nl

prefLabel

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

@en

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

@nl

P1476

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

@en

P2093

Abdul-Hamid Bazarbachi

http://www.w3.org/2001/XMLSchema#string

Ali T Taher

http://www.w3.org/2001/XMLSchema#string

Bachar Chaya

http://www.w3.org/2001/XMLSchema#string

Joseph Sleiman

http://www.w3.org/2001/XMLSchema#string

Rayan Bou-Fakhredin

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice

Hepcidin and iron regulation, 10 years later.

A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload

The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation

Iron Loading and Overloading due to Ineffective Erythropoiesis.

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Renal dysfunction in patients with thalassaemia

Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment

P31

scholarly article

review article

P356

10.3390/IJMS18122778

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maria Domenica Cappellini

P5008

ScienceSource

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29261151

http://www.w3.org/2001/XMLSchema#string

P921

P932

5751376

http://www.w3.org/2001/XMLSchema#string